Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer

Double Blind Study ◽

Double Blind ◽

Abstract PD5-04: Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer

10.1158/1538-7445.sabcs17-pd5-04 ◽

2018 ◽

Author(s):

E de Azambuja ◽

C Saura ◽

P Nuciforo ◽

S Frantal ◽

M Oliveira ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Early Stage ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.

10.1200/jco.2016.34.15_suppl.tps613 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS613-TPS613 ◽

Cited By ~ 2

Author(s):

Cristina Saura ◽

Evandro De Azambuja ◽

Mafalda Oliveira ◽

Peter Christian Dubsky ◽

Dimitrios Zardavas ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Early Stage ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Abstract OT1-03-06: LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/ HER2-negative, early-stage breast cancer

10.1158/1538-7445.sabcs15-ot1-03-06 ◽

2016 ◽

Author(s):

M Oliveira ◽

E de Azambuja ◽

C Saura ◽

P Dubsky ◽

D Zardavas ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Phase Ii ◽

Early Stage ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Abstract OT1-03-09: FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs15-ot1-03-09 ◽

2016 ◽

Cited By ~ 1

Author(s):

C Saura ◽

SJ Isakoff ◽

I Calvo ◽

D Patt ◽

J Andersen ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Neoadjuvant Treatment ◽

Blind Study ◽

Double Blind Study ◽

Akt Inhibitor ◽

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.

10.1200/jco.2016.34.15_suppl.tps1105 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS1105-TPS1105

Author(s):

Steven J. Isakoff ◽

Cristina Saura ◽

Isabel Calvo ◽

Miguel J. Gil Gil ◽

Debra A. Patt ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Neoadjuvant Treatment ◽

Blind Study ◽

Double Blind Study ◽

Akt Inhibitor ◽

FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).

10.1200/jco.2015.33.15_suppl.tps1112 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. TPS1112-TPS1112

Author(s):

Mafalda Oliveira ◽

Cristina Saura ◽

Antonio Gonzalez-Martin ◽

Jay C. Andersen ◽

Julie Gottlieb Fisher ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Early Stage ◽

Neoadjuvant Treatment ◽

Blind Study ◽

Double Blind Study ◽

Akt Inhibitor ◽

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

European Journal of Cancer ◽

10.1016/s0959-8049(99)80705-9 ◽

1999 ◽

Vol 35 ◽

pp. S84 ◽

Cited By ~ 2

Author(s):

E. Bajetta ◽

L.Y. Dirix ◽

L.E. Fein ◽

S.E. Jones ◽

J. Cervek ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Survival Advantage ◽

Advanced Breast ◽

Blind Study ◽

Megestrol Acetate ◽

Phase Iii ◽

Double Blind Study ◽

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30334-1 ◽

2019 ◽

Vol 20 (9) ◽

pp. 1226-1238 ◽

Cited By ~ 20

Author(s):

Cristina Saura ◽

Dominik Hlauschek ◽

Mafalda Oliveira ◽

Dimitrios Zardavas ◽

Anita Jallitsch-Halper ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Oestrogen Receptor ◽

Early Stage ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Trial

Histopathological assessment of anastrozole versus tamoxifen as preoperative treatment in postmenopausal women with T2–4b, N0–2, M0 breast cancer: Results from a randomized, double-blind study

10.1200/jco.2005.23.16_suppl.570 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 570-570 ◽

Cited By ~ 4

Author(s):

H. Tsuda ◽

M. Kurozumi ◽

F. Akiyama ◽

G. Sakamoto ◽

S. Noguchi ◽

...

Keyword(s):

Breast Cancer ◽

Postmenopausal Women ◽

Blind Study ◽

Double Blind Study ◽

Preoperative Treatment ◽

PD01-04: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study.

10.1158/0008-5472.sabcs11-pd01-04 ◽

2011 ◽

Cited By ~ 5

Author(s):

DA Yardley ◽

RR Ismail-Khan ◽

PM Klein

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Histone Deacetylase ◽

Phase Ii ◽

Histone Deacetylase Inhibitor ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Randomized Phase Ii ◽

Deacetylase Inhibitor